Hydrocortisone MR is a Small Molecule owned by Diurnal Group, and is involved in 11 clinical trials, of which 8 were completed, and 3 are ongoing.

Hydrocortisone binds to the cytosolic glucocorticoid receptor. After binding to the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes for the production of cortisol hormone.

The revenue for Hydrocortisone MR is expected to reach a total of $481m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Hydrocortisone MR NPV Report.

Hydrocortisone MR is currently owned by Diurnal Group.

Hydrocortisone MR Overview

Hydrocortisone (Efmody) is a synthetic corticosteroid, acts as an anti-inflammatory agent. It is formulated as modified release hard gelatin capsules for oral route of administration. Efmody is indicated in adult and adolescents of 12 years and over for the treatment of congenital adrenal hyperplasia.

Hydrocortisone MR (Chronocort) is under development for the treatment of Addison's disease and congenital adrenal hyperplasia. The drug candidate is administered orally. Chronocort is a physiological cortisol replacement therapy. Chronocort is a modified release formulation that delivers hydrocortisone in a manner that mimics the body's normal circadian rhythm (the body's natural 24 hour hormone cycle). It was also under development for the treatment of hypopituitarism.

Diurnal Group Overview

Diurnal Group is clinical stage pharmaceutical company that targets patient needs in chronic endocrine (hormonal) diseases. Its pipeline products include DNL-0200, DNL-0300, DNL-0400 and DNL-0500. The company offers treatment for congenital adrenal hyperplasia (CAH), adrenal insufficiency, hypogonadism and hypothyroidism. It offers various products which include thyroxine (T4) tablets, hydrocortisone tablets, and fludrocortisone tablets. Diurnal Group is headquartered in Cardiff, Wales, the UK. Diurnal Group is clinical stage pharmaceutical company that targets patient needs in chronic endocrine (hormonal) diseases. Its pipeline products include DNL-0200, DNL-0300, DNL-0400 and DNL-0500. The company offers treatment for congenital adrenal hyperplasia (CAH), adrenal insufficiency, hypogonadism and hypothyroidism. It offers various products which include thyroxine (T4) tablets, hydrocortisone tablets, and fludrocortisone tablets. Diurnal Group is headquartered in Cardiff, Wales, the UK.

Quick View – Hydrocortisone MR

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Hydrocortisone MR
Administration Pathway
  • Oral
Therapeutic Areas
  • Hormonal Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.